UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

Telephone number:

OMB	APPRO	VAL
-----	-------	-----

OMB Number:3235-0080Expires:March 31, 2018Estimated average burdenhours per response:1.7

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38118

Commission File Number 001-38

Issuer: <u>DermTech, Inc.</u>

Exchange: The Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: Emerald View, Suite 400

2054 Vista Parkway

West Palm Beach FLORIDA 33411

646-321-3444

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

If Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. $\frac{1}{2}$

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2019-11-08	By	Amy Horton	Hearings Advisor
Date		Name	Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. <u>See</u> General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, November 8, 2019, DermTech, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the warrant of DermTech, Inc. (the Company), effective at the opening of the trading session on November 18, 2019. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(a)(3). The Company was notified of the Staffs determination on August 22, 2019. The Company appealed the determinations to a Hearing Panel. On September 3, 2019, the Company was notified that it had not complied with the requirements of IM-5101-22, which served as an additional basis for delisting. Upon review of the information provided by the Company, the Panel issued a decision dated October 16, 2019, declaring that the Company meets the criteria for initial listings on the Exchange, and will, accordingly, continue the Company listing on the Capital Market of the common stock. The Panel further decided to delist the Company warrant, effective at the open of trading on October 18, 2019. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on October 18, 2019.